Clinical Trial Finder

Key

Inclusion Criteria:

Subjects are eligible for enrollment into this study if they meet any of the following criteria (NOTE: This is not an exhaustive list):

• - Subjects aged ≥18 years.

• - ECOG performance status 0 or 1.

• - Subjects must have a documented IDH mutation per immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) testing of tumor tissue.

• - Subjects must have histologically or cytologically documented, advanced or metastatic solid malignancy of any type that has recurred or progressed on available standard treatment and for which no curative therapy exists.

Key

Exclusion Criteria:

Subjects are not eligible for enrollment into this study if they meet any of the following criteria (NOTE: This is not an exhaustive list):

• - Subjects who received an investigational agent <14 days prior to their first day of study drug administration.

• - Subjects who are pregnant or breastfeeding.

• - Subjects with an active severe infection, some treated infections and with an expected or with an unexplained fever >38.3°C during screening visits or on their first day of study drug administration.

• - Subjects with some current or prior heart conditions.

• - Subjects taking medications that are known to prolong the QT interval may not be eligible.

• - Subjects with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.

• - Some subjects with some current or prior gastrointestinal or liver diseases.

- Subjects with inadequate organ function as defined by the protocol

HMPL-306 is a dual IDH1/2 inhibitor.This is a phase 1, open-label, multicenter study to evaluate the safety and tolerability of HMPL-306 administered orally in the treatment of subjects with advanced or metastatic solid tumors with IDH mutation. The study consists of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). The dose escalation part will determine the MTD/RP2D. The dose expansion part will administer the MTD/RP2D to mIDH-positive solid tumor malignancies including, but not limited to, cholangiocarcinoma, skeletal chondrosarcoma, low-grade glioma, perioperative low-grade glioma

Arms

Experimental: Part 1 Dose Escalation Cohorts

Patients from each cohort will be administered HMPL-306 orally QD

Experimental: Part 2 Dose Expansion Cohorts

Patients from each cohort will be administered HMPL-306 orally QD at the recommended phase 2 dose

Interventions

Drug: - HMPL-306

Administered orally QD in a 28-day continuous dosing treatment cycle